Biomarkers of outcome from cardiovascular disease
Standard
Biomarkers of outcome from cardiovascular disease. / Khuseyinova, Natalie; Koenig, Wolfgang.
in: CURR OPIN CRIT CARE, Jahrgang 12, Nr. 5, 10.2006, S. 412-419.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Biomarkers of outcome from cardiovascular disease
AU - Khuseyinova, Natalie
AU - Koenig, Wolfgang
PY - 2006/10
Y1 - 2006/10
N2 - PURPOSE OF REVIEW: Recognition of the fact that low-grade local and systemic inflammation accompanies all stages of atherogenesis has led to the identification of a number of novel biomarkers of cardiovascular risk. We highlight recent epidemiological and experimental evidence concerning four emerging biomarkers: C-reactive protein, interleukin-6, D-dimer and white blood cell count.RECENT FINDINGS: Recent epidemiological and experimental data on C-reactive protein, the most extensively studied marker of systemic inflammation, produced in the liver in response to interleukin-6, has cast some doubt on its clinical utility and causal involvement in atherogenesis. However, a large number of studies still strongly support C-reactive protein as an independent predictor of future cardiovascular risk and a potent proatherogenic agent. Among all markers of inflammation studied to date, C-reactive protein seems the most suitable one for use in clinical practice. Regarding white blood cell count, recent studies focused on the differential leucocyte count in coronary-heart-disease risk assessment; neutrophil count represents the strongest predictor of incident coronary heart disease.SUMMARY: Thus, screening for low-grade inflammation using several novel biomarkers might provide an important tool to identify individuals at increased risk who would benefit most from targeted preventive interventions.
AB - PURPOSE OF REVIEW: Recognition of the fact that low-grade local and systemic inflammation accompanies all stages of atherogenesis has led to the identification of a number of novel biomarkers of cardiovascular risk. We highlight recent epidemiological and experimental evidence concerning four emerging biomarkers: C-reactive protein, interleukin-6, D-dimer and white blood cell count.RECENT FINDINGS: Recent epidemiological and experimental data on C-reactive protein, the most extensively studied marker of systemic inflammation, produced in the liver in response to interleukin-6, has cast some doubt on its clinical utility and causal involvement in atherogenesis. However, a large number of studies still strongly support C-reactive protein as an independent predictor of future cardiovascular risk and a potent proatherogenic agent. Among all markers of inflammation studied to date, C-reactive protein seems the most suitable one for use in clinical practice. Regarding white blood cell count, recent studies focused on the differential leucocyte count in coronary-heart-disease risk assessment; neutrophil count represents the strongest predictor of incident coronary heart disease.SUMMARY: Thus, screening for low-grade inflammation using several novel biomarkers might provide an important tool to identify individuals at increased risk who would benefit most from targeted preventive interventions.
KW - Atherosclerosis/blood
KW - Biomarkers/blood
KW - C-Reactive Protein/analysis
KW - Coronary Disease/blood
KW - Fibrin Fibrinogen Degradation Products/analysis
KW - Humans
KW - Inflammation/blood
KW - Interleukin-6/blood
KW - Leukocyte Count
KW - Mass Screening
U2 - 10.1097/01.ccx.0000244119.16377.75
DO - 10.1097/01.ccx.0000244119.16377.75
M3 - SCORING: Review article
C2 - 16943718
VL - 12
SP - 412
EP - 419
JO - CURR OPIN CRIT CARE
JF - CURR OPIN CRIT CARE
SN - 1070-5295
IS - 5
ER -
